Biohaven stocks up on experimental drugs with new acquisition, licensing deal

On Friday, Biohaven Pharmaceutical disclosed two deals — one with a small biotechnology company, the other with Bristol Myers Squibb — that are meant to outfit its pipeline with experimental drugs for epilepsy and a rare neuromuscular disorder.